Midlife smoking, apolipoprotein e and risk of dementia and Alzheimer's disease: A population-based cardiovascular risk factors, aging and dementia study

Dementia and Geriatric Cognitive Disorders

Volumn 30, Issue 3, 2010, Pages 277-284

  Rusanen, M ^a,b   Rovio, S ^f   Ngandu, T ^a,c   Nissinen, A ^c   Tuomilehto, J ^c,d,e   Soininen, H ^a,b   Kivipelto, M ^a,f  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e SOUTH OSTROBOTHNIA CENTRAL HOSPITAL   (Finland)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer's disease; Apolipoprotein E; Cohort study; Dementia; Population based study; Risk factors; Smoking

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON4; UNCLASSIFIED DRUG;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DEMENTIA; FEMALE; FOLLOW UP; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

AGED; AGING; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DEMENTIA; FEMALE; FINLAND; GENOTYPE; HEALTH SURVEYS; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; ODDS RATIO; RISK FACTORS; SEX FACTORS; SMOKING; SOCIOECONOMIC FACTORS; SWEDEN;

EID: 77956577144     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320484     Document Type: Article

References (35)

1. Bartecchi CE, MacKenzie TD, Schrier RW: The human costs of tobacco use. N Engl J Med 1994; 330:907-912.
2. Graves AB, van Duijn CM, Chandra V, Fratiglioni L, Heyman A, Jorm AF, Kokmen E, Kondo K, Mortimer JA, Rocca WA, et al: Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative reanalysis of casecontrol studies. EURO-DEM Risk Factors Research Group. Int J Epidemiol 1991; 20(suppl 2):S48-S57.
3. Lee PN: Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 1994; 13: 131-144 .
4. van Duijn CM, Clayton DG, Chandra V, Fratiglioni L, Graves AB, Heyman A, Jorm AF, Kokmen E, Kondo K, Mortimer JA, et al: Interaction between genetic and environmental risk factors for Alzheimer's disease: a reanalysis of casecontrol studies. EURO-DEM Risk Factors Research Group. Genet Epidemiol 1994; 11:539-551.
5. Riggs JE: Smoking and Alzheimer's disease: protective effect or differential survival bias? Lancet 1993; 342:793-794.
6. Wang HX, Fratiglioni L, Frisoni GB, Viitanen M, Winblad B: Smoking and the occurrence of Alzheimer's disease: crosssectional and longitudinal data in a populationbased study. Am J Epidemiol 1999; 149:640-644.
7. van Duijn CM, Havekes LM, van Broeckhoven C, de Knijff P, Hofman A: Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease. BMJ 1995; 310 : 627-631.
8. Doll R, Peto R, Boreham J, Sutherland I: Smoking and dementia in male British doctors: prospective study. BMJ 2000; 320:1097-1102.
9. Ott A, Slooter AJ, Hofman A, van Harskamp F, Witteman JC, van Broeckhoven C, van Duijn CM, Breteler MM: Smoking and risk of dementia and Alzheimer's disease in a populationbased cohort study: the Rotterdam study. Lancet 1998; 351: 1840-1843.
10. Launer LJ, Andersen K, Dewey ME, Letenneur L, Ott A, Amaducci LA, Brayne C, Copeland JR, Dartigues JF, Kragh-Sorensen P, Lobo A, Martinez-Lage JM, Stijnen T, Hofman A: Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology 1999; 52:78-84.
11. Merchant C, Tang MX, Albert S, Manly J, Stern Y, Mayeux R: The inf luence of smoking on the risk of Alzheimer's disease. Neurology 1999; 52:1408-1412 .
12. Tyas SL, White LR, Petrovitch H, Webster Ross G, Foley DJ, Heimovitz HK, Launer LJ: Midlife smoking and latelife dementia: the Honolulu-Asia Aging Study. Neurobiol Aging 2003; 24: 589-596.
13. Aggarwal NT, Bienias JL, Bennett DA, Wilson RS, Morris MC, Schneider JA, Shah RC, Evans DA: The relation of cigarette smoking to incident Alzheimer's disease in a biracial urban community population. Neuroepidemiolog y 2006; 26: 140-146 .
14. Reitz C, den Heijer T, van Duijn C, Hofman A, Breteler MM: Relation between smoking and risk of dementia and Alzheimer disease: the Rotterdam study. Neurology 2007; 69: 998-1005.
15. Vartiainen E, Puska P, Jousilahti P, Korhonen HJ, Tuomilehto J, Nissinen A: Twentyyear trends in coronary risk factors in north Karelia and in other areas of Finland. Int J Epidemiol 1994; 23: 495-504.
16. Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A: Midlife vascular risk factors and latelife mild cognitive impairment: a populationbased study. Neurology 20 01; 56: 1683-1689.
17. WHO MONICA Project Principal Investigators: World Health Organization MONICA Project (Monitoring Trends and Determinants in Cardiovascular Disease): a major international collaboration. J Clin Epidemiol 1988; 41:105-114.
18. Tsukamoto K, Watanabe T, Matsushima T, Kinoshita M, Kato H, Hashimoto Y, Kurokawa K, Teramoto T: Determination by PCR-RFLP of Apo E genotype in a Japanese population. J Lab Clin Med 1993; 121: 598-602.
19. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
20. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
22. 7-receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Res 1998; 779:359-363.
23. Akaike A, Tamura Y, Yokota T, Shimohama S, Kimura J: Nicotineinduced protection of cultured cortical neurons against JV-methyl-D-aspartate receptormediated glutamate cytotoxicity. Brain Res 1994; 644: 181-187.
24. Zeng H, Zhang Y, Peng L, Shao H, Menon NK, Yang J, Salomon AR, Freidland RP, Zagorski MG: Nicotine and amyloid formation. Biol Psychiatry 2001; 49: 248-257.
25. Ono K, Hasegawa K, Yamada M, Naiki H: Nicotine breaks down preformed Alzheimer's pamyloid fibrils in vitro. Biol Psychiatry 2002; 52: 880-886.
26. Rusted JM, Newhouse PA, Levin ED: Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease. Behav Brain Res 2000; 113:121-129.
27. Levin ED, Simon BB: Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 1998; 138: 217-230.
28. 3 H]nicotine binding sites in human brain. J Neurochem 1988; 50:1243-1247.
29. Markesbery WR: Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997; 23: 134-147.
30. Kivipelto M, Rovio S, Ngandu T, Kareholt I, Eskelinen M, Winblad B, Hachinski V, Cedazo-Minguez A, Soininen H, Tuomilehto J, Nissinen A: Apolipoprotein E e4 magnifies lifestyle risks for dementia: a populationbased study. J Cell Mol Med 2008; 12: 2762-2771.
31. Cedazo-Minguez A, Cowburn RF: Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. J Cell Mol Med 2001; 5:254-266.
32. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a metaanalysis. APOE and Alzheimer Disease Meta-Analysis Consortium. JAMA 1997; 278: 1349-1356.
33. de Groot LC, Verheijden MW, de Henauw S, Schroll M, van Staveren WA: Lifestyle, nutritional status, health, and mortality in elderly people across Europe: a review of the longitudinal results of the SENECA study. J Gerontol A Biol Sci Med Sci 2004; 59: 1277-1284.
34. Ewbank DC: The APOE gene and differences in life expectancy in Europe. J Gerontol A Biol Sci Med Sci 2004; 59: 16-20 .
35. Schiele F, de Bacquer D, Vincent-Viry M, Beisiegel U, Ehnholm C, Evans A, Kafatos A, Martins MC, Sans S, Sass C, Visvikis S, de Backer G, Siest G: Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis 2000; 152:475-488.